ID   E006AA-hT
AC   CVCL_X480
SY   E006AA-highly Tumorigenic
DR   ATCC; CRL-3277
DR   cancercelllines; CVCL_X480
DR   Wikidata; Q38514377
RX   PubMed=25076860;
RX   PubMed=30787054;
RX   PubMed=31416301;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Parent cell line (E006AA) has been shown to be a 786-O derivative.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00586.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8
ST   D16S539: 12
ST   D5S818: 9
ST   D7S820: 11
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4834 ! E006AA
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 05-10-23; Version: 15
//
RX   PubMed=25076860; DOI=10.7150/ijbs.9406;
RA   Koochekpour S., Willard S.S., Shourideh M., Ali S., Liu C.-H.,
RA   Azabdaftari G., Saleem M., Attwood K.;
RT   "Establishment and characterization of a highly tumorigenic African
RT   American prostate cancer cell line, E006AA-hT.";
RL   Int. J. Biol. Sci. 10:834-845(2014).
//
RX   PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132;
RA   Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P.,
RA   Mitra R., Nonn L., Kimbro K.S., Kittles R.A.;
RT   "Genetic ancestry analysis reveals misclassification of commonly used
RT   cancer cell lines.";
RL   Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019).
//
RX   PubMed=31416301; DOI=10.1002/pros.23800;
RA   Koochekpour S., Maresh G.A., Katner A., Parker-Johnson K., Lee T.-J.,
RA   Hebert F.E., Kao Y.S., Skinner J., Rayford W.;
RT   "Correction: Establishment and characterization of a primary
RT   androgen-responsive African-American prostate cancer cell line,
RT   E006AA. Prostate 2004;60(2):145-152.";
RL   Prostate 79:815-815(2019).
//